Results 231 to 240 of about 10,462,861 (343)

Vedolizumab as induction and maintenance therapy for Crohn's disease.

open access: yesNew England Journal of Medicine, 2013
W. Sandborn   +16 more
semanticscholar   +1 more source

Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency

open access: yesObesity, EarlyView.
ABSTRACT Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin‐melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations.
Ellina Lytvyak   +2 more
wiley   +1 more source

Crohn??s Disease [PDF]

open access: yesJournal of Occupational and Environmental Medicine, 1968
openaire   +2 more sources

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

open access: yes, 1997
S. Targan   +8 more
semanticscholar   +1 more source

The N‐Glycome to Differentiate Mesenchymal Stem Cells Upon Chondrogenic Differentiation, Dedifferentiation, and Senescence

open access: yesPROTEOMICS, EarlyView.
ABSTRACT Mesenchymal stem cells (MSCs) are adult stem cells able to self‐renewal or differentiation into different cell types, including chondrocytes. N‐Glycans are post‐translational modifications of glycoproteins that contribute to vital cell functions.
Houda Montacir   +4 more
wiley   +1 more source

Using machine learning to predict clinical remission with exclusive enteral nutrition in pediatric Crohn disease. [PDF]

open access: yesJ Pediatr Gastroenterol Nutr
Suarez RGS   +17 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy